Researchers from Rice University and Baylor College of Medicine are hoping a first-of-its-kind “glyco-immune” checkpoint inhibitor could be the key to stopping bone cancer metastasis for breast cancer survivors.   Breast cancer often migrates to other organs. As many as 40% of breast cancer survivors are diagnosed with metastatic cancer, sometimes years after their initial treatment. Bone metastasis is involved in more than two-thirds of those cases, and bone metastatic lesions are known to “seed”...

Some people who have Alzheimer’s disease pathology never get dementia because they have a protective biological mechanism working in their favor, a new study suggests.   Researchers at the University of Texas Medical Branch studied postmortem brains and found that people who presented with brain pathology consistent with fully symptomatic Alzheimer’s disease—but not dementia—also had preserved autophagy, a physiological system that allows cells to recycle or eliminate junk and clutter.   “This is significant, because...

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.   The OS was 7.4 months with fruquintinib versus 4.8 months in the placebo arm, while the median PFS was 3.7 months with fruquintinib compared to 1.8 months in the placebo arm. These results represent a statistically significant improvement relative to controls....

Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).   Findings from the Phase Ib cohort of the KRYSTAL-1 trial represent the first prospective data of anti-tumor activity from a KRAS G12C inhibitor in brain metastases, providing continued evidence of the drug’s efficacy.   The targeted...